Calithera Biosciences Inc. (CALA) Shares Up 7%
Calithera Biosciences Inc. (NASDAQ:CALA)’s share price shot up 7% during mid-day trading on Wednesday . The stock traded as high as $3.23 and last traded at $3.21, with a volume of 220,787 shares trading hands. The stock had previously closed at $3.00.
A number of equities analysts have weighed in on the stock. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Zacks Investment Research downgraded shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, May 17th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Calithera Biosciences has a consensus rating of “Buy” and a consensus target price of $10.38.
The firm’s market capitalization is $59.52 million. The company has a 50 day moving average of $3.57 and a 200 day moving average of $4.93.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.05. On average, equities analysts expect that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.